A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study

INTRODUCTION: Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. METHO...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Kidney Int Rep
Main Authors: Charytan, Chaim, Manllo-Karim, Roberto, Martin, Edouard R., Steer, Dylan, Bernardo, Marializa, Dua, Sohan L., Moustafa, Moustafa A., Saha, Gopal, Bradley, Charles, Eyassu, Meraf, Leong, Robert, Saikali, Khalil G., Liu, Cameron, Szczech, Lynda, Yu, Kin-Hung P.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2021
Assuntos:
Clinical Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8258588/
https://ncbi.nlm.nih.gov/pubmed/34307977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2021.04.007
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares